Epileptic seizure

Epilepsy Foundation Rolls Out #StaySafeSide to Promote Seizure First Aid

Retrieved on: 
Monday, October 21, 2019
Health, Medicine, Clinical medicine, Epileptic seizure, Seizure types, Epilepsy

LANDOVER, Md., Oct. 21, 2019 /PRNewswire/ -- November is National Epilepsy Awareness Month and the Foundation is rolling out #StaySafeSide, a nationwide effort to highlight the importance of recognizing a seizure and promote seizure first aid.

Key Points: 
  • LANDOVER, Md., Oct. 21, 2019 /PRNewswire/ -- November is National Epilepsy Awareness Month and the Foundation is rolling out #StaySafeSide, a nationwide effort to highlight the importance of recognizing a seizure and promote seizure first aid.
  • "While we promote awareness throughout the year, this initiative comes at a time when more education is needed to increase public knowledge about epilepsy and seizure first aid," said Philip M. Gattone, M.Ed., president and CEO of the Epilepsy Foundation.
  • That's why, this November, we challenge everyone to join our National Epilepsy Awareness Month efforts to end epilepsy by learning seizure first aid and educating others in their community."
  • With a network of nearly 50 partners throughout the United States, the Epilepsy Foundation is leading the fight to END EPILEPSY.

EPILEPSY SURVEY GIVES VOICE TO PATIENTS IN SETTING THEIR RESEARCH PRIORITIES

Retrieved on: 
Wednesday, October 16, 2019
Epileptic seizure, RTT, Caregiver

Patients, caregivers and clinicians will use the survey results to compile this list and prioritise which questions are the most important for research to address.

Key Points: 
  • Patients, caregivers and clinicians will use the survey results to compile this list and prioritise which questions are the most important for research to address.
  • Survey results will be shared with research organizations and funding agencies across Canada, bringing the needs of patients and caregivers to the forefront and giving them the power to shape the national epilepsy research agenda.
  • EpLink The Epilepsy Research Program of the Ontario Brain Institute is dedicated to reducing seizures and improving quality of life for people with epilepsy through research.
  • We work with industry partners, patients, caregivers, and community epilepsy agency representatives to bring our research to the community.

Epilepsy Foundation Teams Up with Omaze to Offer a Once-in-a-Lifetime Experience to Meet Lady Gaga and Attend Her Vegas Residencies

Retrieved on: 
Tuesday, October 8, 2019
Health, Medicine, Clinical medicine, Omaze, Epilepsy Foundation, Epilepsy in animals, Epileptic seizure, Epilepsy, Seizure types

Fans donating as little as $10 to benefit the Epilepsy Foundation get 100 chances to win this unique experience.

Key Points: 
  • Fans donating as little as $10 to benefit the Epilepsy Foundation get 100 chances to win this unique experience.
  • Proceeds from the campaign support the Epilepsy Foundation's efforts to END EPILEPSY, accelerate therapies to stop seizures, find cures and save lives.
  • "We are excited to kick off this campaign with Omaze and honored that Lady Gaga partnered with Omaze to benefit the Epilepsy Foundation and offer this experience to her fans," said Geoff DeLizzio, chief development officer, Epilepsy Foundation.
  • Over a lifetime, one in 10 people will have a seizure, and one in 26 will be diagnosed with epilepsy.

Knopp Biosciences Reports Data Demonstrating Restoration of Function by KB-3061 in Cellular Model of Gene Variants Causing KCNQ2 Epileptic Encephalopathy

Retrieved on: 
Tuesday, September 17, 2019
Biotechnology, FDA, Health, Pharmaceutical, Other Science, Research, General Health, Genetics, Science, Clinical trials, Branches of biology, Biology, Electrophysiology, Ion channels, Proteins, KvLQT2, Channelopathies, M current, Epileptic seizure

When treated with KB-3061, the function of the mutated channels was fully restored, producing normal Kv7.2 channel current density.

Key Points: 
  • When treated with KB-3061, the function of the mutated channels was fully restored, producing normal Kv7.2 channel current density.
  • The disease is caused by dominant-negative mutations in the KCNQ2 gene, which normally produces a potassium channel, Kv7.2, critical to early brain development.
  • The results suggest that restoring suppressed Kv7.2 channel activity may ameliorate the dysfunction caused by KCNQ2 gene mutations.
  • As previously announced by Knopp, KB-3061 has also demonstrated potent seizure control in an in vivo model of epilepsy.

Epilepsy Foundation Rolls Out Seizure Safe Schools Initiative Nationwide

Retrieved on: 
Monday, September 16, 2019
Health, Medicine, Clinical medicine, Epilepsy Foundation, Epilepsy, Epileptic seizure, Seizure

LANDOVER, Md., Sept. 16, 2019 /PRNewswire/ -- Epilepsy Foundation today announced it is rolling out its Seizure Safe Schools initiative nationwide.

Key Points: 
  • LANDOVER, Md., Sept. 16, 2019 /PRNewswire/ -- Epilepsy Foundation today announced it is rolling out its Seizure Safe Schools initiative nationwide.
  • "For students living with epilepsy, it is important that schools are well-equipped with the tools necessary to provide a safe and enriching environment," said Laura Weidner, vice president, Government Relations & Advocacy, Epilepsy Foundation.
  • In April 2018, Kentucky became the first state to pass into law the Lyndsey Crunk Act (HB 147), which helped to create the model bill for the Seizure Safe Schools initiative.
  • In collaboration with the Epilepsy Foundation of Kentuckiana, Lyndsey Crunk a 17-year-old Epilepsy Foundation Teens Speak Up!

Engage Therapeutics to Present at the 21st Annual H.C. Wainwright Global Investment Conference

Retrieved on: 
Monday, September 9, 2019
RTT, Clinical medicine, Medicine, GABAA receptor positive allosteric modulators, Epileptic seizure, Health, Epilepsy, Alprazolam

SUMMIT, N.J., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Engage Therapeutics, Inc ., a clinical-stage biopharmaceutical company developing an inhaled benzodiazepine for the abortive treatment of seizures in patients with prolonged focal, generalized or cluster epileptic seizure episodes, will participate in the 21st Annual H.C. Wainwright Global Investment Conference this week in New York City.

Key Points: 
  • SUMMIT, N.J., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Engage Therapeutics, Inc ., a clinical-stage biopharmaceutical company developing an inhaled benzodiazepine for the abortive treatment of seizures in patients with prolonged focal, generalized or cluster epileptic seizure episodes, will participate in the 21st Annual H.C. Wainwright Global Investment Conference this week in New York City.
  • Gregory T. Mayes, President and CEO of Engage Therapeutics, will present a company overview on Tuesday, Sept. 10, at 5:05 p.m.
  • Engage Therapeutics is developing Staccato alprazolam for the immediate cessation of active and acute epileptic seizures.
  • Engage Therapeutics is based in Summit, N.J. For additional information, please see www.engagetherapeutics.com .

Over 99% Of EEG Epileptic Abnormalities Can Be Detected By EEG Systems Without Midline Or Parasagittal Leads

Retrieved on: 
Monday, August 26, 2019
Branches of biology, Medicine, Clinical medicine, Electrophysiology, Neurophysiology, Neurotechnology, Electrodiagnosis, Electroencephalography, Epileptic seizure, Epilepsy, Triage

According to the findings of this study, less than 1% of EEGs show midline or parasagittal focal epileptic abnormalities.

Key Points: 
  • According to the findings of this study, less than 1% of EEGs show midline or parasagittal focal epileptic abnormalities.
  • Conventional EEG systems with more electrodes provide better spatial information, however the value of midline and parasagittal electrodes in the evaluation of epileptic activity has not been thoroughly addressed.
  • This study sought to retrospectively review EEG data from 300 patients and compiled literature cases in a meta-analysis to assess the scope of abnormalities captured exclusively by midline parasagittal leads.
  • The objective was to confirm the ability of systems that do not have midline or parasagittal leads to triage seizure activity.

The Ceribell Rapid Response EEG Codesigned with Whipsaw Wins Gold and Silver Medals and Voted "Best in Show" at 2019 MDEAs

Retrieved on: 
Thursday, July 18, 2019
Branches of biology, Medicine, Neuroscience, Electrodiagnosis, Neurotechnology, Electrophysiology, Neurophysiology, Emerging technologies, Electroencephalography, Epileptic seizure

The end product is a reimagined portable electroencephalogram which hospital technicians can now use to promptly detect non-convulsive brain seizures.

Key Points: 
  • The end product is a reimagined portable electroencephalogram which hospital technicians can now use to promptly detect non-convulsive brain seizures.
  • Traditional bulky EEG machines require patients to hold still for an extended period of time with electrode wires attached to their scalps.
  • In response, Whipsaw worked closely with Ceribell to design a sleek alternative consisting of a disposable headband and mobile control unit.
  • Ceribell EEG represents design at its finest: where an old problem is completely turned upside down to discover a superior solution.

Persons With Alzheimer's Disease More Likely To Experience Recurring Epileptic Seizures

Retrieved on: 
Monday, July 15, 2019
Epilepsy, Medicine, Health, Clinical medicine, Seizure types, Epileptic seizure, RTT, Neonatal seizure, Frontal lobe epilepsy

Also reported at AAIC 2019, persons with dementia are at higher risk of having recurring seizures and of experiencing seizures for the first time at a younger age, compared to people without dementia.

Key Points: 
  • Also reported at AAIC 2019, persons with dementia are at higher risk of having recurring seizures and of experiencing seizures for the first time at a younger age, compared to people without dementia.
  • Alzheimer's disease causes death of neurons, and researchers hypothesize this may contribute to abnormal electrical activity in the brain that leads to epileptic seizures.
  • Seizures can be a symptom of epilepsy, but not all people who experience seizures have epilepsy.
  • And persons with Alzheimer's disease were also twice as likely to have had a previous seizure (3.14% vs. 1.57%).

NIH Study to Utilize NeuroPace RNS System for Research on the Brain’s Reward System

Retrieved on: 
Thursday, July 11, 2019
Nursing, Managed care, Health, Mental health, Medical devices, Research, Science, Clinical trials, Branches of biology, Neurotechnology, Neuroscience, Medicine, Neuroprosthetics, Responsive neurostimulation device, Electrotherapy, Medical devices, RNS, Epilepsy, Neurostimulation, Epileptic seizure, the RNS® System, NeuroPace

Were pleased to support this new research, which will be among the first to explore additional applications of the RNS System beyond epilepsy.

Key Points: 
  • Were pleased to support this new research, which will be among the first to explore additional applications of the RNS System beyond epilepsy.
  • As part of the study, the RNS System will provide the first long-term ambulatory recordings of human brain activity from this key area of the reward circuit, the nucleus accumbens.
  • The RNS System is the worlds first and only closed-loop brain-responsive neurostimulation system designed to prevent epileptic seizures at their source.
  • The companys first product, the RNS System, is the only FDA-approved brain-responsive neurostimulator for the treatment of focal onset refractory epilepsy.